BRD2 and male infertility: Although significantly more validation with larger clinical test sets is needed for both the infertility DMR biomarkers and FSH therapeutic responder DMR biomarkers, the current study provides the proof of concept that epigenetic biomarkers potentially exist and may be used in the diagnosis and potential treatment of male idiopathic infertility.